Clinical trials: latest news

Clinical trials resources

  • Clinical trials

    This factsheet provides a brief introduction to the types of clinical trial that people with HIV might be asked to join. There is also information on how...

    From: Factsheets

    Information level Level 2
  • HIV and clinical trials

    Clinical trials for people with HIV are currently testing treatments in six broad categories, at all stages of HIV disease: Treatments intended to attack HIV at different...

    From: Factsheets

    Information level Level 2
  • Thinking about joining a clinical trial?

    People decide to take part in clinical trials for different reasons. It is something that is best decided in close consultation with your healthcare team. Generally, it...

    From: Factsheets

    Information level Level 2

Clinical trials features

Clinical trials in your own words

Clinical trials news from aidsmap

More news

Clinical trials news selected from other sources

  • 'Give HIV drugs to healthy gay men'

    Healthy gay men should be offered daily HIV drugs to prevent infections, say UK Medical Research Council and Public Health England scientists. Their study, on 545 high-risk men, found one case of HIV could be stopped for every 13 men treated for a year. The research team says it would be similar to the pill for women and would not encourage risky sex. The findings have been described as a "game changer" and the NHS is considering how to adopt them.

    25 February 2015 | BBC News
  • The Search for a Permanent Alternative to HIV Drugs

    Researchers Carefully Tailor a Study to Find Patients to Test Going Off Antiretroviral Medication

    16 February 2015 | Wall Street Journal
  • Failed Trial in Africa Raises Questions About How to Test HIV Drugs

    The failure of the VOICE trial of H.I.V.-prevention methods in Africa — and the elaborate deceptions employed by the women in it — have opened an ethical debate about how to run such studies in poor countries and have already changed the design of some that are now underway.

    05 February 2015 | New York Times
  • New anti HIV drug dolutegravir is effective at low doses

    The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

    21 January 2015 | MMD Newswire
  • Pressure grows for Europe to subsidize HIV prevention drug Truvada

    HIV-AIDS organizations are urging European health authorities to approve and subsidize the use of HIV prevention drug Truvada as infections slowly rise across the continent.

    02 December 2014 | Deutsche Welle
  • START Study Could Change How We Look at HIV Treatment, and HIV Itself

    Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.

    25 November 2014 | The Body
  • D-day for The Pill for HIV

    The media coverage of the unexpectedly early success of two trials of pre-exposure prophylaxis - PrEP - has generally been positive, sometimes overly so. But I haven't seen anything that actually explains why the results of the PROUD and IPERGAY studies are so important, or why they represent a gear-change in the accelerating race towards the end of HIV.

    05 November 2014 | Huffington Post
  • NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns

    ​A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period. The trial aims to build on the case of the 'Mississippi Baby'.

    05 November 2014 | National Institute of Allergy and Infectious Diseases (NIAID) press release
  • Advocates Applaud Launch of MTN-017, World’s First Phase II Rectal Microbicide Study

    IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.

    02 October 2014 | IRMA
  • New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

    An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

    09 September 2014 | HIVandhepatitis.com
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.